The New Frontier of JAK Inhibitors: Significant Therapeutic Response to Tofacitinib in a Patient With Granulomatous Reaction to Filler in the Buttocks.

IF 2.3 4区医学 Q2 DERMATOLOGY

Journal of Cosmetic Dermatology Pub Date : 2024-10-15 DOI:10.1111/jocd.16578

Parvin Mansouri, Susan Farshi

引用次数: 0

Abstract

Background: Recent research has demonstrated that Janus Kinase (JAK) inhibitors can be effective in treating refractory granulomatous diseases.

Case presentation: We report the case of a 50-year-old woman who developed a granulomatous reaction following a filler injection in her buttocks.

Management: The patient was treated with tofacitinib, and after 1 year of therapy, the stiffness and swelling resolved without any side effects.

Conclusion: Tofacitinib appears to be a viable option for the treatment of granulomatous reactions to fillers.

查看原文本刊更多论文

JAK 抑制剂的新领域：一名臀部填充物肉芽肿反应患者对托法替尼的显著治疗反应

背景：最新研究表明，Janus 激酶（JAK）抑制剂可有效治疗难治性肉芽肿疾病：我们报告了一名50岁女性的病例，她在臀部注射填充剂后出现了肉芽肿反应：患者接受了托法替尼治疗，治疗一年后，僵硬和肿胀症状消失，且无任何副作用：结论：托法替尼似乎是治疗填充剂肉芽肿反应的可行方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cosmetic Dermatology DERMATOLOGY-

CiteScore

4.30

自引率

13.00%

发文量

818

审稿时长

>12 weeks

期刊介绍： The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques. The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.